Pappas Tours Novocure in Portsmouth
Portsmouth, NH – Earlier this month, Congressman Chris Pappas (NH-01) joined with Novocure leadership to tour their facility in Portsmouth to learn more about their vital work of striving to extend survival in some of the most aggressive forms of cancer through the development and commercialization of Novocure's innovative therapy, Tumor Treating Fields.
Pappas also met with employees and held a town hall meeting following the tour to take questions and give an update on his work in Washington. Pappas spoke about the need to invest in our infrastructure, support small businesses, and ensure we have the workforce necessary to compete in a 21st-century economy.
"Novocure is an incredible asset to New Hampshire's First District not only as an employer but as a company on the cutting edge of medical innovation," said Rep. Pappas. "Their work to pioneer new cancer treatments is literally changing the lives of patients around the world. I enjoyed learning more about the important work being done by Novocure, meeting with employees and taking questions, and discussing how the federal government can continue to support medical innovation and development."
"Congressman Pappas is a forward-thinking and dynamic leader for the state of New Hampshire," said Bill Doyle, Novocure's Executive Chairman. "Novocure is lucky to have him representing Portsmouth in Congress, where he can work with us to advocate for patient access to groundbreaking medical technology. We enjoyed hosting the Congressman in our rapidly expanding Portsmouth facility to show him the exciting work and high-quality jobs we bring to the area. We hope to have him back for another visit soon."
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information, visitwww.novocure.com or follow @Novocure on LinkedIn and Twitter.
For more information about the work Congressman Pappas is doing in Congress, visit https://pappas.house.gov or follow on social media at @RepChrisPappas.